F. Leclerc, F. ). Dijon, P. Gestraud, and ;. Zeitouni, Alban Lermine (Institut Curie, Lionel Perrier (Institut Paoli-Calmettes

B. Tran, J. E. Dancey, and S. Kamel-reid, Cancer genomics: technology, discovery, and translation, J Clin Oncol, vol.30, pp.647-660, 2012.

A. M. Tsimberidou, N. G. Iskander, and D. S. Hong, Personalized medicine in a phase I clinical trials program: The M.D. Anderson Cancer Center Initiative, J Clin Oncol, vol.29, 2011.

M. Arnedos, F. André, and F. Farace, The challenge to bring personalized cancer medicine from clinical trials into routine clinical practice: the case of the institut gustave roussy, Mol Oncol, vol.6, pp.204-210, 2012.

V. Hoff, D. D. Stephenson, J. J. Rosen, and P. , Pilot study using molecular profiling of patients' tumors to find potential targets and select treatments for their refractory cancers, J Clin Oncol, vol.28, pp.4877-4883, 2010.

J. H. Doroshow, Selecting systemic cancer therapy one patient at a time: is there a role for molecular profiling of individual patients with advanced solid tumors?, J Clin Oncol, vol.28, pp.4869-4871, 2010.

M. Buyse, E. Quinaux, and A. Hendlisz, Progression-free survival ratio as end point for phase II trials in advanced solid tumors, J Clin Oncol, vol.29, pp.451-452, 2011.

L. Tourneau, C. Servois, V. Diéras, and V. , Tumour growth kinetics assessment: added value to RECIST in cancer patients treated with molecularly targeted agents, Br J Cancer, vol.106, pp.854-857, 2012.

K. L. Blackwell, H. J. Burstein, and A. M. Storniolo, Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study, J Clin Oncol, vol.30, pp.2585-2592, 2012.

H. T. Arkenau, J. Barriuso, and D. Olmos, Prospective validation of a prognostic score to improve patient selection for oncology phase I trials, J Clin Oncol, vol.27, pp.2692-2696, 2009.

E. Horstmann, M. S. Mccabe, and L. Grochow, Risks and benefits of phase 1 oncology trials, N Engl J Med, vol.352, pp.895-904, 1991.

H. Schwarzenbach, D. S. Hoon, and K. Pantel, Cell-free nucleic acids as biomarkers in cancer patients, Nat Rev Cancer, vol.11, pp.426-437, 2011.

D. R. Parkinson, N. Dracopoli, G. Petty, and B. , Considerations in the development of circulating tumor cell technology for clinical use, J Transl Med, vol.10, p.138, 2012.

M. J. Higgins, D. Jelovac, and E. Barnathan, Detection of tumor PIK3CA status in metastatic breast cancer using peripheral blood, Clin Cancer Res, vol.18, pp.3462-3469, 2012.

J. C. Soria, C. Massard, and H. Izzedine, From theoretical synergy to clinical supra-additive toxicity, J Clin Oncol, vol.27, pp.1359-1361, 2009.

M. Gerlinger, A. J. Rowan, and S. Horswell, Intratumor heterogeneity and branched evolution revealed by multiregion sequencing, N Engl J Med, vol.366, pp.883-892, 2012.

E. A. Eisenhauer, P. Therasse, and J. Bogaerts, New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1), Eur J Cancer, vol.45, pp.228-247, 2009.